ReviewDiagnostics (Basel, Switzerland)2023
Research Progress of Respiratory Disease and Idiopathic Pulmonary Fibrosis Based on Artificial Intelligence.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Applications of AI/ML in accelerating the development of pulmonary drug delivery system.Acta pharmaceutica Sinica. B · 2026Review
- Bridging Artificial Intelligence and Medical Education: Navigating the Alignment Paradox.ATS scholar · 2025Review
- Integrating Radiomics Signature into Clinical Pathway for Patients with Progressive Pulmonary Fibrosis.Diagnostics (Basel, Switzerland) · 2025Review
- Integrating CT radiomics and clinical data with machine learning to predict fibrosis progression in coalworker pneumoconiosis.Frontiers in medicine · 2025Article
- Revolutionizing Pulmonary Diagnostics: A Narrative Review of Artificial Intelligence Applications in Lung Imaging.Cureus · 2024Review
- Detection of various lung diseases including COVID-19 using extreme learning machine algorithm based on the features extracted from a lightweight CNN architecture.Biocybernetics and biomedical engineering · 2023Article
- Improving Dental Implant Outcomes: CNN-Based System Accurately Measures Degree of Peri-Implantitis Damage on Periapical Film.Bioengineering (Basel, Switzerland) · 2023Article
- Diabetes Detection Models in Mexican Patients by Combining Machine Learning Algorithms and Feature Selection Techniques for Clinical and Paraclinical Attributes: A Comparative Evaluation.Journal of diabetes research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Machine Learning (ML) is an algorithm based on big data, which learns patterns from the previously observed data through classifying, predicting, and optimizing to accomplish specific tasks. In recent years, there has been rapid development in the field of ML in medicine, including lung imaging analysis, intensive medical monitoring, mechanical ventilation, and there is need for intubation etiology prediction evaluation, pulmonary function evaluation and prediction, obstructive sleep apnea, such as biological information monitoring and so on. ML can have good performance and is a great potential tool, especially in the imaging diagnosis of interstitial lung disease. Idiopathic pulmonary fibrosis (IPF) is a major problem in the treatment of respiratory diseases, due to the abnormal proliferation of fibroblasts, leading to lung tissue destruction. The diagnosis mainly depends on the early detection of imaging and early treatment, which can effectively prolong the life of patients. If the computer can be used to assist the examination results related to the effects of fibrosis, a timely diagnosis of such diseases will be of great value to both doctors and patients. We also previously proposed a machine learning algorithm model that can play a good clinical guiding role in early imaging prediction of idiopathic pulmonary fibrosis. At present, AI and machine learning have great potential and ability to transform many aspects of respiratory medicine and are the focus and hotspot of research. AI needs to become an invisible, seamless, and impartial auxiliary tool to help patients and doctors make better decisions in an efficient, effective, and acceptable way. The purpose of this paper is to review the current application of machine learning in various aspects of respiratory diseases, with the hope to provide some help and guidance for clinicians when applying algorithm models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.